Etoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes | Zendy

Nicholson Matthew C. | Zendy; Naeije Leonie | Zendy; Hayden Anna R. | Zendy; Mattman Andre | Zendy; Dix David | Zendy; Chen Luke Y.C. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Etoposide‐based treatment of adult HLH is associated with high biochemical response but poor survival outcomes

Author(s) -

Nicholson Matthew C.,

Naeije Leonie,

Hayden Anna R.,

Mattman Andre,

Dix David,

Chen Luke Y.C.

Publication year - 2020

Publication title -

ejhaem

Language(s) - English

Resource type - Journals

ISSN - 2688-6146

DOI - 10.1002/jha2.57

Subject(s) - etoposide , medicine , ferritin , retrospective cohort study , serum ferritin , pediatrics , gastroenterology , chemotherapy

Etoposide‐based treatment is the standard of care for adult HLH in many centers, yet there remains a paucity of data regarding treatment outcomes. We conducted a retrospective study of 23 adults treated with etoposide‐based therapy compared to 10 pediatric HLH cases at a single center. At diagnosis, the median serum ferritin was 20,071 µg/L and 937 µg/L in adults and children, respectively; median sIL‐2r was 14,524 U/mL and 4,478 U/mL. Biochemical response to treatment was high, with 21/23 adults achieving >75% reduction in serum ferritin, but one year survival was only 7/21 compared to 7/10 in pediatric cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research